GSK acquires Canadian biotech firm 35Pharma in 950 million dollar cash deal
GSK reached an agreement today to acquire Canadian biopharmaceutical firm 35Pharma for 950 million dollars in cash. The deal marks a significant expansion.
Insights:
GSK plc announced on February 25, 2026, that it has reached an agreement to acquire 35Pharma Inc, a biopharmaceutical company based in Canada 
CA, for a total cash consideration of $950 million. The transaction, which was made public today, represents a material corporate acquisition for both entities involved and will result in the transfer of ownership of 35Pharma Inc to GSK.
CA, for a total cash consideration of $950 million. The transaction, which was made public today, represents a material corporate acquisition for both entities involved and will result in the transfer of ownership of 35Pharma Inc to GSK.
